查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841958

美國血液檢測市場規模、佔有率和趨勢分析報告：按檢測類型和細分市場預測，2025-2033 年

U.S. Blood Testing Market Size, Share & Trends Analysis Report By Test Type, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國血液檢測市場摘要

預計 2024 年美國血液檢測市場規模將達到 359 億美元，到 2033 年將達到 714.1 億美元，2025 年至 2033 年的複合年成長率為 8.1%。

糖尿病、心血管疾病和癌症等慢性疾病的發生率不斷上升是該市場的主要驅動力，這些疾病需要頻繁的診斷測試和監測才能有效管理。

預防性醫療保健的轉變以及社會意識的增強，鼓勵人們定期體檢和篩檢，以便及早發現疾病，是推動這一市場發展的主要動力。 2024年，美國疾病管制與預防中心 (CDC) 加強了其核心檢測能力，以檢測和應對高優先病原體。近期的技術創新提高了血液檢測的可及性和效率，成為市場擴張的重要催化劑。例如，2024年6月，美國食品藥物管理局 (FDA) 批准了第一個照護現場C型肝炎病毒(HCV) RNA 檢測的上市許可。此檢測只需透過指尖採血樣本，即可在一次就診中完成檢測和治療。

預計將影響該市場的其他關鍵技術進步包括：

人工智慧的整合：人工智慧和機器學習在解讀複雜的血液檢測數據、實現更早的疾病檢測、自動化抹片分析、改進生物標記識別以及減少診斷錯誤方面發揮著至關重要的作用。這些系統加快了結果交付速度，並在靈敏度和特異性方面達到甚至超過了臨床金標準。

實驗室晶片技術：微型設備能夠在一次滴血中處理多項血液測試，從而大大減少實驗室需求，改善偏遠和資源有限地區的使用，並支援快速的照護現場診斷。

穿戴式生物感測器和智慧型裝置（如葡萄糖和血紅蛋白追蹤器）現在可以實現即時、連續的血液成分監測，當與遠端醫療平台相結合時，可以改善慢性病管理、患者參與度以及對健康狀況變化的快速反應。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國血液檢測市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國血液檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國血液檢測市場：檢測類型估計與趨勢分析

  • 測試類型細分儀表板
  • 美國血液檢測市場：檢測類型變化分析
  • 美國血液檢測市場規模與趨勢分析（按檢測類型，2021-2033）
  • 血糖檢測
  • A1C 測試
  • 直接 LDL 檢測
  • 血脂檢查
  • 攝護腺特異性抗原檢測
  • COVID-19檢測
  • 尿素氮檢測
  • 維生素D檢測
  • 甲狀腺刺激素檢測
  • 血清尼古丁/可替寧檢測
  • 高敏感CRP檢測
  • 睪酮測試
  • ALT 測試
  • 皮質醇測試
  • 肌酸酐檢測
  • AST測試
  • 其他血液檢查

第5章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • Abbott
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc.
    • BIOMERIEUX
    • Biomerica
    • BD
    • Quest Diagnostics Incorporated
    • Siemens Healthineers AG
    • Danaher Corporation
    • Trinity Biotech Plc
Product Code: GVR-4-68040-754-0

U.S. Blood Testing Market Summary

The U.S. blood testing market size was valued at USD 35.90 billion in 2024 and is projected to reach USD 71.41 billion by 2033, growing at a CAGR of 8.1% from 2025 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which necessitate frequent diagnostic testing and monitoring for effective management.

Growing public awareness and a shift toward preventive healthcare, encouraging routine check-ups and early disease detection screening, are the major drivers for this market. In 2024, the Centers for Disease Control and Prevention (CDC) strengthened its core laboratory capabilities to detect and respond to high-priority pathogens. Recent technological innovations are a major catalyst for the market's expansion, improving the accessibility and efficiency of blood testing. For instance, in June 2024, the FDA granted marketing authorization for the first point-of-care Hepatitis C virus (HCV) RNA test, which enables single-visit testing and treatment using a fingertip blood sample.

Other key technological advances that are expected to impact this market are:

Artificial Intelligence Integration: AI and machine learning were pivotal in interpreting complex blood test data, enabling earlier disease detection, automation of smear analysis, improved biomarker identification, and reduced diagnostic errors. These systems accelerated result delivery and matched or exceeded clinical gold standards in sensitivity and specificity.

Lab-on-a-Chip Technology: Miniaturized devices capable of processing multiple blood tests on a single drop dramatically reduce laboratory demands, increasing access in remote and resource-limited regions while supporting rapid point-of-care diagnostics.

Wearable Biosensors: Smart devices (e.g., glucose and hemoglobin trackers) became possible for monitoring real-time, continuous blood composition. These are integrated with telemedicine platforms, improving chronic disease management, patient engagement, and rapid response to changes in health.

U.S. Blood Testing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood testing market report based on test type:

  • Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
    • Glucose Testing
    • A1C Testing
    • Direct LDL testing
    • Lipid panel testing
    • Prostate-specific antigen testing
    • COVID-19 testing
    • BUN testing
    • Vitamin D testing
    • Thyroid-stimulating hormone testing
    • Serum Nicotine / Cotinine testing
    • High sensitivity CRP testing
    • Testosterone testing
    • ALT testing
    • Cortisol testing
    • Creatinine testing
    • AST testing
    • Other blood tests

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Blood Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Blood Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Blood Testing Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Segment Dashboard
  • 4.2. U.S. Blood Testing Market: Test Type Movement Analysis
  • 4.3. U.S. Blood Testing Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Billion)
  • 4.4. Glucose Testing
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.5. A1C Testing
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.6. Direct LDL testing
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.7. Lipid Panel Testing
    • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.8. Prostate-Specific Antigen Testing
    • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.9. Covid-19 Testing
    • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.10. BUN Testing
    • 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.11. Vitamin D Testing
    • 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.12. Thyroid-Stimulating Hormone Testing
    • 4.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.13. Serum Nicotine/Cotinine Testing
    • 4.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.14. High Sensitivity CRP Testing
    • 4.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.15. Testosterone Testing
    • 4.15.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.16. ALT Testing
    • 4.16.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.17. Cortisol Testing
    • 4.17.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.18. Creatinine Testing
    • 4.18.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.19. AST Testing
    • 4.19.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.20. Other Blood Tests
    • 4.20.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. Key company heat map analysis, 2024
  • 5.4. Company Profiles
    • 5.4.1. Abbott
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. F. Hoffmann-La Roche Ltd
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Bio-Rad Laboratories, Inc.
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. BIOMERIEUX
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Biomerica
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. BD
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Quest Diagnostics Incorporated
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Siemens Healthineers AG
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Danaher Corporation
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Trinity Biotech Plc
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. blood testing market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Table 3 U.S. blood testing market, by test type, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. blood testing market: market outlook
  • Fig. 10 Blood testing competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. blood testing market driver impact
  • Fig. 16 U.S. blood testing market restraint impact
  • Fig. 17 U.S. blood testing market strategic initiatives analysis
  • Fig. 18 U.S. blood testing market: Test type movement analysis
  • Fig. 19 U.S. blood testing market: Test type outlook and key takeaways
  • Fig. 20 Glucose testing market estimates and forecast, 2021 - 2033
  • Fig. 21 A1C testing market estimates and forecast, 2021 - 2033
  • Fig. 22 Direct LDL testing market estimates and forecast, 2021 - 2033
  • Fig. 23 Lipid panel testing market estimates and forecast, 2021 - 2033
  • Fig. 24 Prostate-specific antigen testing market estimates and forecast, 2021 - 2033
  • Fig. 25 COVID-19 testing market estimates and forecast, 2021 - 2033
  • Fig. 26 BUN testing market estimates and forecast, 2021 - 2033
  • Fig. 27 Vitamin D testing market estimates and forecast, 2021 - 2033
  • Fig. 28 Thyroid-stimulating hormone (TSH) market estimates and forecast, 2021 - 2033
  • Fig. 29 Serum nicotine/cotinine market estimates and forecast, 2021 - 2033
  • Fig. 30 High sensitivity CRP testing market estimates and forecast, 2021 - 2033
  • Fig. 31 Testosterone testing market estimates and forecast, 2021 - 2033
  • Fig. 32 ALT testing market estimates and forecast, 2021 - 2033
  • Fig. 33 Cortisol testing market estimates and forecast, 2021 - 2033
  • Fig. 34 Creatinine testing market estimates and forecast, 2021 - 2033
  • Fig. 35 AST testing market estimates and forecast, 2021 - 2033
  • Fig. 36 Other blood tests market estimates and forecast, 2021 - 2033